Results 181 to 190 of about 19,278,359 (237)

Engineered Peptide Self‐Assembled Nanofibers for Enhanced STING Activation: A Promising Nanodelivery Platform for Immunotherapy of Pediatric Solid Tumors

open access: yesAdvanced Science, EarlyView.
An engineered peptide self‐assembled nanofiber platform, designed to replicate STING–cGAMP binding motifs, facilitates pH‐responsive cytosolic delivery of cGAMP, enhances the endoplasmic reticulum with high efficiency, and robustly activates the STING pathway.
Yubin He   +6 more
wiley   +1 more source

AI‐Designed TREM1‐Targeted LYTAC Nanoparticles Reprogram the Neuroimmune Microenvironment in Traumatic Brain Injury

open access: yesAdvanced Science, EarlyView.
AI‐enabled de novo design of a TREM1 binder, integrated into a BBB‐crossing and macrophage‐targeted nanoplatform, enables TREM1 degradation and attenuates neuroinflammation, thereby promoting neuroprotection and tissue repair after traumatic brain injury. ABSTRACT Secondary neuroinflammation drives progressive damage after traumatic brain injury (TBI),
Yimin Huang   +19 more
wiley   +1 more source

Non‐Coding Transcripts From Diversified Members of IgLec Family Protect Antiviral Effectors From Viral miRNA

open access: yesAdvanced Science, EarlyView.
The IgLec gene family generates both protein‐coding antiviral effectors and non‐coding transcripts. Upon viral infection, non‐coding transcripts are preferentially targeted by viral miR‐N48, thereby buffering protein‐coding isoforms from repression. Depletion of these decoy transcripts compromises antiviral defense, revealing a non‐coding RNA‐mediated ...
Ying Huang   +5 more
wiley   +1 more source

A Multi‐Targeting Chimeric Antigen Receptor‐T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non‐Small Cell Lung Cancer

open access: yesAdvanced Science, EarlyView.
A dual‐transmembrane Bicephali CAR‐T platform simultaneously targets CD276 and NKG2D ligands to address antigen heterogeneity in non‐small cell lung cancer. By improving immune synapse formation, mitochondrial fitness, antioxidant capacity, and stem‐like persistence, this design enhances durable tumor control and provides a versatile strategy to ...
Lina Wang   +8 more
wiley   +1 more source

SLC25A4high Hepatocytes Enhance Lifestyle Intervention Response in MASLD by Recruiting Eating Macrophages

open access: yesAdvanced Science, EarlyView.
SLC25A4high hepatocytes drive metabolic‐associated steatotic liver disease (MASLD) remission by recruiting lipid‐eating macrophages. The hepatocyte Slc25a4/PANX1/ATP/P2ry12 axis mediates find‐me signaling that triggers macrophage recruitment and efferocytosis, while recruited macrophages secrete GDF15 to activate hepatocyte PPARα and promote fatty acid
Yiting Qian   +8 more
wiley   +1 more source

Anti-D immunoglobulin in children with newly diagnosed immune thrombocytopenic purpura: a pilot study

open access: yesHaematologica, 2000
PM Monteleone   +3 more
doaj  

The Yorkshire Antenatal Anti-D Immunoglobulin Trial in Primigravidae.

Lancet, The, 1983
2069 Rh(D)-negative women in their first pregnancy received 100 micrograms doses of anti-D immunoglobulin at 28 and 34 weeks' gestation and a further dose at delivery if the infant was Rh(D)-positive. The antibody status was determined at 28 weeks, 34 weeks, at delivery, and 6 months after delivery.
L A Tovey
exaly   +3 more sources

Should Anti-D Immunoglobulin Be Given Antenatally?

Lancet, The, 1980
A survey of 246 Rh-negative expectant mothers who had Rh antibodies for the first time has shown that in about 50% sensitisation might have been prevented had anti-D immunoglobulin (Ig) been injected after delivery of the previous Rh-positive baby. Sensitisation of the other mothers could have been prevented only by giving anti-D Ig antenatally during ...
Geoffreyh Tovey
exaly   +3 more sources

Anti-D-Rh0-immunoglobulin

Reactions Weekly, 1996
▲ Anti-D-Rh0 immunoglobulin (WinRho SD) is the only virally inactivated polyclonal antibody used in preventing the destruction of antibody/platelet complexes in patients with immune thrombocytopenic purpura (ITP) ▲ Its main mechanism of action appears to be via Fc receptor blockade but immunomodulatory mechanisms have also been postulated ...
Urs E. Nydegger, E. Rewald
  +5 more sources

Home - About - Disclaimer - Privacy